Online Only Articles

Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Department of Hematology AZ St-Jan Brugge-Oostende, Belgium
EORTC Headquarters, Brussels, Belgium
Hematology, Sapienza University, Rome, Italy
Department of Hematology, Radboud University, Medical Center, Nijmegen, the Netherlands
Department of Hematology, Leiden University Medical Center, the Netherlands
Department of Hematology and of Biomedicine and Prevention, Tor Vergata University, Rome, Italy
EORTC Headquarters, Brussels, Belgium;Department of Hematology, Istituto Europeo di Oncologia, Milan, Italy
Jeroen Bosch Medical Center, Den Bosch, the Netherlands
EORTC Headquarters, Brussels, Belgium
Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA), Rome, Italy
Department of Hematology, Hôpital Saint-Antoine, APHP, Paris, France
Department of Hematology, Institut Jules Bordet, ULB, Brussels, Belgium
Department of Tumorimmunology, Radboud University, Medical Center, Nijmegen, the Netherlands
Department of Hematology and of Biomedicine and Prevention, Tor Vergata University, Rome, Italy
Department of Hematology, Leiden University Medical Center, the Netherlands
GIGA-I3-Hematology, University of Liège, Belgium
Vol. 102 No. 2 (2017): February, 2017 https://doi.org/10.3324/haematol.2016.153130